4 High-Risk Stocks Built for Big Returns
High-risk stocks do what they say on the tin. They offer investors high return potential, but investors always need to appreciate the risk. That said, constructing a diversified portfolio and spreading stock-specific risk around to try to hit a few big winners is a viable strategy. That includes stocks like electric vertical takeoff and landing (eVTOL) maker Joby Aviation (NYSE: JOBY), weight loss drug company Viking Therapeutics (NASDAQ: VKTX), Navitas Semiconductor (NASDAQ: NVTS), and Agios Pharmaceuticals (NASDAQ: AGIO).
The Food and Drug Administration (FDA) is undertaking a priority review of Agios’s oral pyruvate kinase (PK) activator, mitapivat. It is set to respond to Agios’s supplemental New Drug Application (sNDA) for mitapivat to treat sickle cell disease (SCD) by Nov. 1.
Agios already had mitapivat approved to treat pyruvate kinase deficiency and adult thalassemia. An approval would expand Agios’s total addressable market for a drug that’s already established in the market for other indications. Given that the Wall Street consensus, according to Visible Alpha, is for mitapivat (SCD) to contribute about a third of total company revenue by 2030, it’s clear that an approval will provide upside potential for the stock.
Source: www.fool.com — article syndicated from the publisher’s feed; all rights remain with the original publisher.